Management of basal cell carcinoma by surveyed dermatologists in Scotland

Gudi, V.; Ormerod, Anthony; Dawn, G.; Green, C; MacKie, Rona M.; Douglas, W.S.; Gupta, Geeta

doi:10.1111/j.1365-2230.2006.02199.x

Cited by 17 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surgery is still considered the first‐line treatment and is by far the most frequent treatment option in various European countries . Standard excision is an effective treatment for all primary BCCs, with a 5‐year recurrence rate of 2–10% .…”

Section: Resultsmentioning

confidence: 99%

Is early detection of basal cell carcinoma worthwhile? Systematic review based on the WHO criteria for screening

et al. 2016

View full text Add to dashboard Cite

The incidence of basal cell carcinoma (BCC) has risen three- to fourfold over the last 30 years and is expected to continue to increase with ageing of the population. Although BCC has a good prognosis, it causes significant morbidity and has an important impact on the public health budget due to direct treatment costs. Based on the existing evidence, a systematic evaluation of the World Health Organization criteria was performed to determine whether earlier detection of BCC could reduce morbidity and cost. BCC slowly increases in size, with a median increase in diameter of 0·5 mm over 10 weeks. There is an important delay in diagnosis ranging from 19 to 25 months. In several studies BCC size was the main determinant of treatment cost, surgical complexity, reconstruction technique and the specific surgical procedure performed, such as Mohs micrographic surgery or surgical excision. One study showed that size also seems to affect the cost per treatment for other nonsurgical options. The use of vismodegib, an inhibitor of the hedgehog pathway, is confined to locally advanced or metastatic BCC. Delays in diagnosis and appropriate treatment are the most important underlying causes in the occurrence of giant BCC and/or BCC with metastasis. Although the latter represent only a very small fraction of all BCCs, the majority of them are located in the facial region. The available data point to a slow increase in the size of BCCs over time. Size is one of the major determinants in choice of treatment and the associated cost, especially for facial BCC. Therefore we conclude that current data support early detection and adequate management of BCCs on the face.

show abstract

Section: Resultsmentioning

confidence: 99%

Is early detection of basal cell carcinoma worthwhile? Systematic review based on the WHO criteria for screening

et al. 2016

View full text Add to dashboard Cite

show abstract

“…4 Surgery is still considered the first-line treatment in different European countries, and 57-87% of all BCCs are still treated by standard excision (SE). [5][6][7][8] In the current observational literature, 5-year recurrence rates for Mohs micrographic surgery (MMS) are reported to be 1Á0-6Á5% for primary BCC and 4Á0-10Á0% for recurrent tumours. 9-15 A large, 10-year followup randomized controlled trial of high-risk facial BCCs showed a difference of 7Á8% for primary and 9Á6% for recurrent BCCs in favour of MMS over SE, although only the latter reached statistical significance.…”

Section: Discussionmentioning

confidence: 98%

Mohs micrographic surgery for basal cell carcinoma: evaluation of the indication criteria and predictive factors for extensive subclinical spread

Hoorens

Batteauw

Maele³

et al. 2016

Br J Dermatol

View full text Add to dashboard Cite

show abstract

“…Reported rates of incomplete excision after routine excision ranges from 1.9% to 16% (Table 1). [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16] In a recent study by Leibovitch and colleagues of Mohs micrographic surgery (MMS) in Australia, 11,127 BCC cases were referred for MMS; the reason for referral in 33.1% cases was tumor recurrence. 17 Factors contributing to incomplete excision include difficulty in establishing clinical margins, especially when prior cryotherapy has destroyed tissue architecture, and in certain histologic subtypes with poorly defined macroscopic borders.…”

Section: Ncomplete Excision Of Basal Cell Carcinoma (Bcc)mentioning

confidence: 99%

Incompletely Excised Basal Cell Carcinoma: Residual Tumor Rates at Mohs Re-Excision

Palmer

Wilson

2013

Dermatologic Surgery

View full text Add to dashboard Cite

Immediate re-excision using MMS is recommended for treatment of incompletely excised BCC because the majority of cases have histologically detectable BCC. Watch and wait advice could lead to significant morbidity because recurrence may necessitate more extensive closures and costs. Long-term follow-up is recommended. It is important to conduct self-audits of incomplete excisions and follow up these patients.

show abstract

Management of basal cell carcinoma by surveyed dermatologists in Scotland

Abstract: In general, BCCs are managed according to BAD guidelines in Scotland, but waiting times vary considerably.

Cited by 17 publications

References 19 publications

Is early detection of basal cell carcinoma worthwhile? Systematic review based on the WHO criteria for screening

Is early detection of basal cell carcinoma worthwhile? Systematic review based on the WHO criteria for screening

Mohs micrographic surgery for basal cell carcinoma: evaluation of the indication criteria and predictive factors for extensive subclinical spread

Incompletely Excised Basal Cell Carcinoma: Residual Tumor Rates at Mohs Re-Excision

Contact Info

Product

Resources

About